Nephros Inc: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 23, 2023 and accepted by EDGAR at Mar 23, 2023, 21:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $10.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $5.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $4.7m | us-gaap:GrossProfit |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2022-01-01 to 2022-12-31 | $7.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$4.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $20.0k | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$7.1m | us-gaap:ProfitLoss |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.73 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$3.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $137.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $3.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $8.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $11.0m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $1.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $2.1m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $71.0k | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-12-31 | $5.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-23-008716. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.